Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:COLL NASDAQ:VNDA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOLLCollegium Pharmaceutical$37.80-3.9%$35.34$27.84▼$50.79$1.27B0.76507,405 shs697,981 shsVNDAVanda Pharmaceuticals$6.28-1.7%$7.57$3.81▼$9.94$384.26M0.651.17 million shs1.31 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOLLCollegium Pharmaceutical0.00%+16.66%+17.70%-17.35%+45.46%VNDAVanda Pharmaceuticals0.00%-10.00%-12.35%-15.59%+45.89%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOLLCollegium Pharmaceutical$37.80-3.9%$35.34$27.84▼$50.79$1.27B0.76507,405 shs697,981 shsVNDAVanda Pharmaceuticals$6.28-1.7%$7.57$3.81▼$9.94$384.26M0.651.17 million shs1.31 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOLLCollegium Pharmaceutical0.00%+16.66%+17.70%-17.35%+45.46%VNDAVanda Pharmaceuticals0.00%-10.00%-12.35%-15.59%+45.89%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOLLCollegium Pharmaceutical 2.67Moderate Buy$57.5052.12% UpsideVNDAVanda Pharmaceuticals 2.50Moderate Buy$14.90137.26% UpsideCurrent Analyst Ratings BreakdownLatest COLL and VNDA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/20/2026VNDAVanda Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/20/2026COLLCollegium Pharmaceutical HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$60.003/19/2026COLLCollegium Pharmaceutical Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$54.00 ➝ $56.003/5/2026COLLCollegium Pharmaceutical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy (B-) ➝ Hold (C+)3/5/2026VNDAVanda Pharmaceuticals Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$18.002/26/2026COLLCollegium Pharmaceutical Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$56.00 ➝ $54.002/23/2026VNDAVanda Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$22.00 ➝ $24.002/18/2026VNDAVanda Pharmaceuticals Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold2/11/2026VNDAVanda Pharmaceuticals Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy2/10/2026COLLCollegium Pharmaceutical Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$58.00(Data available from 5/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOLLCollegium Pharmaceutical$780.57M1.57$14.65 per share2.58$9.64 per share3.92VNDAVanda Pharmaceuticals$216.10M1.75N/AN/A$4.67 per share1.34Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOLLCollegium Pharmaceutical$62.87M$1.7118.537.12N/A9.41%95.18%16.39%N/AVNDAVanda Pharmaceuticals-$220.47M-$3.73N/AN/AN/A-109.99%-32.26%-23.43%N/ALatest COLL and VNDA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026COLLCollegium Pharmaceutical$1.52$1.76+$0.24$0.40$184.47 million$193.52 million5/6/2026Q1 2026VNDAVanda Pharmaceuticals-$0.6880-$0.82-$0.1320-$0.82$54.98 million$51.72 million2/26/2026Q4 2025COLLCollegium Pharmaceutical$2.20$2.04-$0.16$0.46$206.36 million$205.45 million2/11/2026Q4 2025VNDAVanda Pharmaceuticals-$2.18-$2.39-$0.21-$2.39$59.28 million$57.22 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCOLLCollegium PharmaceuticalN/AN/AN/AN/AN/AVNDAVanda PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOLLCollegium Pharmaceutical2.571.811.48VNDAVanda Pharmaceuticals0.012.162.38Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOLLCollegium PharmaceuticalN/AVNDAVanda Pharmaceuticals88.14%Insider OwnershipCompanyInsider OwnershipCOLLCollegium Pharmaceutical1.85%VNDAVanda Pharmaceuticals10.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCOLLCollegium Pharmaceutical21032.41 million31.81 millionOptionableVNDAVanda Pharmaceuticals29060.13 million54.12 millionOptionableCOLL and VNDA HeadlinesRecent News About These CompaniesVanda Pharmaceuticals (NASDAQ:VNDA) Downgraded by Wall Street Zen to "Strong Sell"May 9 at 1:34 AM | marketbeat.comVanda Pharmaceuticals Inc. Q1 2026 Earnings Call SummaryMay 8 at 8:30 AM | finance.yahoo.comVanda Pharmaceuticals Bets Big on Growth PipelineMay 7 at 10:32 PM | tipranks.comVanda Pharmaceuticals Announces Participation at May 2026 Investor ConferencesMay 7 at 6:44 PM | prnewswire.comUniversal Beteiligungs und Servicegesellschaft mbH Sells 160,000 Shares of Vanda Pharmaceuticals Inc. $VNDAMay 7 at 8:33 AM | marketbeat.comVanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q1 2026 Earnings Call TranscriptMay 7 at 8:31 AM | insidermonkey.comVanda Pharmaceuticals Inc. (VNDA) Q1 2026 Earnings Call TranscriptMay 7 at 6:11 AM | seekingalpha.comVanda Pharmaceuticals Q1 Earnings Call HighlightsMay 7 at 4:17 AM | marketbeat.comVanda (VNDA) Q1 2026 Earnings Call TranscriptMay 7 at 1:23 AM | finance.yahoo.comVanda Pharmaceuticals (VNDA) Reports Q1 Loss, Lags Revenue EstimatesMay 6 at 6:11 PM | zacks.comVanda Pharmaceuticals (NASDAQ:VNDA) Posts Quarterly Earnings Results, Misses Expectations By $0.13 EPSMay 6 at 4:49 PM | marketbeat.comVanda Pharmaceuticals Reports First Quarter 2026 Financial ResultsMay 6 at 4:01 PM | prnewswire.comWall Street Analysts Predict a 105.03% Upside in Vanda (VNDA): Here's What You Should KnowMay 5, 2026 | zacks.comVanda Pharmaceuticals shares rise on Nereus commercial launchMay 5, 2026 | investing.comVanda Pharmaceuticals Inc. (NASDAQ:VNDA) Given Consensus Rating of "Moderate Buy" by AnalystsMay 5, 2026 | marketbeat.comVanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 YearsMay 4, 2026 | prnewswire.comVNDA stock rises after hours on commercial launch of motion sickness drugMay 2, 2026 | msn.comAIGH Capital Management LLC Takes Position in Vanda Pharmaceuticals Inc. $VNDAMay 2, 2026 | marketbeat.comVanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 YearsMay 1, 2026 | prnewswire.comVanda Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026April 29, 2026 | prnewswire.comVanda Pharmaceuticals (VNDA) Expected to Announce Quarterly Earnings on WednesdayApril 29, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCOLL and VNDA Company DescriptionsCollegium Pharmaceutical NASDAQ:COLL$37.80 -1.53 (-3.89%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$37.78 -0.02 (-0.05%) As of 05/8/2026 04:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.Vanda Pharmaceuticals NASDAQ:VNDA$6.28 -0.11 (-1.72%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$6.43 +0.15 (+2.36%) As of 05/8/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SoundHound’s Bottom Is In—Inflection and 50% Upside Ahead? Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus AppLovin Pops After Earnings With Growth Catalysts in Sight Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
